Skip to main content
. 2020 Oct 28;10:585292. doi: 10.3389/fonc.2020.585292

Figure 3.

Figure 3

ARL4C overexpression decreases Erlotinib resistance of lung cancer cells. (A) Left: qPCR quantification of ARL4C expression in HCC827/ER ARL4C-overexpressing (HCC827/ER-ARL4C-OE), HCC827/ER-Vector (HCC827/ER-Vector), and HCC827/ER (control) cells. Right: qPCR quantification of ARL4C expression in PC-9/ER ARL4C-overexpressing (PC-9/ER-ARL4C-SH), PC-9/ER-ARL4C-control (PC-9/ER-Vector), and PC-9/ER (control) cells. (B) Western blotting detection of ARL4C expression in HCC827/ER-ARL4C-OE, HCC827/ER-Vector, and HCC827/ER (control) cells. (C) Western blotting detection of ARL4C expression in PC-9/ER-ARL4C-OE, PC-9/ER vector, and PC-9/ER (control) cells. (D,E) Erlotinib IC50 for HCC827/ER and PC-9 /ER cells ARL4C overexpressing with HBLV-ARL4C-SH3 and Vector measured by MTS. (F,G) Colony formation of HCC827/ER-ARL4C-OE, HCC827/ER-Vector, and HCC827/ER (control) cell. (H,I) Colony formation of PC-9/ER-ARL4C-OE, PC-9/ER-vector, and PC-9/ER (control) cells. (J) Transwell assay of the migration of HCC827/ER-ARL4C-OE, HCC827/ER-Vector, and HCC827/ER (control) cells. (K) Transwell assay of the migration of PC-9/ER-ARL4C-OE, PC-9/ER-vector, and PC-9/ER (control) cells. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.